Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment was written by Bellesi, Silvia;Sali, Michela;Maiolo, Elena;Pereyra Boza, Maria del Carmen;Alma, Eleonora;Palucci, Ivana;Fatone, Federica;De Maio, Flavio;Viscovo, Marcello;D’Alo, Francesco;De Stefano, Valerio;Hohaus, Stefan;Sanguinetti, Maurizio. And the article was included in Leukemia & Lymphoma in 2022.Computed Properties of C16H21Cl2N3O2 The following contents are mentioned in the article:
Here, we show that patients vaccinated with the anti-SARS-CoV2 vaccine during active immunochemotherapy including the anti-CD20 Mab rarely (3.7%) show a Nab response, while the majority of patients vaccinated during cytotoxic therapy obtained a seroprotective. Response (80%). Still, Nab titers appeared to be lower in chemotherapy-treated patients with respect to a HC group. It is an open question whether routine control of Nab responses in these patients will be useful to estimate the individual level of protection against SARS-CoV2. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Computed Properties of C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Computed Properties of C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem